Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin that is Lilly’s top selling drug, bringing in almost $700 ...

Insulin lispro, the rapid-acting component of Humalog Mix75/25, has been shown to be equipotent to Regular human insulin on a molar basis. Instruct patients on diet, exercise, blood or urine ...

However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population ...

Despite being off-patent for many years, Humalog and other insulin brands continue to make high sales, with Lilly booking around $3 billion from its product last year, $1.8 billion of which was ...

DiMarchi is the inventor of Lilly's insulin analogue Lispro (marketed as Humalog), covered by patent ... result in less self-association and more rapid therapeutic onset. The '477 patent issued ...

Advocates for diabetes patients who need insulin ... short-acting insulin. Which insulin brands are in shortage and why?

A 10 ml vial of Sanofi's long-acting insulin Lantus ... or what's used in a insulin pump), the prices are in such lockstep that you can't see 2 lines. Lilly's Humalog cost $20.82 in 1996 and ...